SABCS 20 continues today with a full schedule of world-class programming, including two General Sessions featuring cutting-edge abstract presentations and expert discussions, the William L. McGuire Memorial Lecture, and four in-depth Spotlight Sessions.

A Special Session on day one of SABCS 20 featured an international roster of clinicians, researchers and patients who shared their professional and personal stories about breast cancer care during the COVID-19 pandemic.

An SABCS Special Session examined the influence of socio-economic factors on access to care, personalized medicine for underserved populations, and how policy changes have affected disparities among breast cancer patients.

While there are many known benefits of breast cancer screening, including a reduction in breast cancer death, there are some potential drawbacks that clinicians need to consider, according to Philippe Autier, MD, PhD.

Clinical trials ultimately exist to improve patient care through development of new therapeutic agents and regimens that allow patients to live longer, healthier lives; however, clinical trials are not always designed with the patient participant in mind.

The Food and Drug Administration’s Breakthrough Therapy Designation (BTD) pathway produced three new breast cancer treatments in 2020, including two antibody-drug conjugates.

The SABCS Virtual Exhibit Hall offers great opportunities to network and learn about the latest in products and services related to breast cancer research and treatment. The SABCS Virtual Exhibit Hall is open from 10:00 am to 3:00 pm CT each day of the Symposium.